Search
ASCERTAIN: EHA joins consortium aiming for better pricing and reimbursement models
November 28, 2022
EHA is a partner in the ASCERTAIN consortium which will develop models for the pricing, cost-benefit assessment, and reimbursement of innovative health technologies in Europe.
EHA at ICH meeting: Excessive bureaucracy harms patient safety and innovation
To solicit input from a wide range of non-ICH members about the revision of ICH E8(R1), ICH held a Public Meeting on ICH E8(R1) “General Considerations for Clinical Studies” (Silver Spring, USA, October 31, 2019).
Read moreFUNDING ALERT: Calls published on ATMPs, T cells and cancer research
In recent weeks, two Calls for proposals were published that offer relevant funding opportunities for hematologists:
1.
EHA-AHA hematology tutorial on Biology and Management of Myeloid Malignancies
In 2016, a new hematology center opened in Yerevan, which offers new services, enabling professionals working there to apply theoretical knowledge and advanced approaches in everyday practice.
Read moreThe importance of education and collaboration for the treatment of patients
This article is written in the context of EHA’s membership of the European Alliance for Personalised Medicine (EAPM) where EHA takes a lead in the development of a strategy for education in personalized medicine. Read the full article here
Read morePRESS RELEASE: Cyprus Presidency promotes win-win on health and competitiveness
The report, “Building an Open Innovation ecosystem in Europe for healthcare”, will be launched at a press conference in the European Parliament in Brussels on 29 November, 2012.
Read moreEHA mapping of adolescent and young adult (AYA) hematology patient care
EHA has launched a major consultation to understand patient care for Adolescents and Young Adults (AYA) with hematological diagnoses across Europe.
Read moreAddressing immunoglobulin shortages: EHA and EBA’s strategic recommendations at the EMA
In recent years, shortages of immunoglobulins (Ig) have become a growing concern in the European Union (EU). Since 2018, the European Medicines Agency (EMA)—the EU agency that evaluates and supervises medicines—has received an increasing number of shortage reports.
Read moreEHA Guidelines on Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults
Chronic myelomonocytic leukemia (CMML) is a disease of the elderly, and by far the most frequent overlap myelodysplastic/myeloproliferative neoplasm in adults.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- »